V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310009870 | 310005348 | 1.74 | 69 | null | 2017-11-01 | 2017-11-08 | Triple Intrathecal | N | N | 310025400 | PEG INTERFERON |
| 310009871 | 310005349 | 1.55 | 90 | Curative (C) | 2017-01-23 | 2017-01-23 | BEVACIZUMAB + CARBO | 02 | N | 310025413 | GEMCITABINE + OXALIPLATIN |
| 310009872 | 310005350 | 1.57 | null | null | 2016-07-14 | 2016-07-15 | R GCVP | N | N | 310025414 | VEMURAFENIB |
| 310009873 | 310005352 | null | 94.3 | Palliative (P) | 2014-08-18 | 2014-08-18 | PEG INTERFERON | N | N | 310025420 | DACARBAZINE |
| 310009874 | 310005354 | 1.67 | 14.9 | Palliative (P) | 2015-03-07 | 2015-03-07 | IMATINIB | 2 | N | 310025478 | ATEZOLIZUMAB |
| 310009875 | 310005356 | 1.6 | null | Palliative (P) | 2014-11-21 | 2014-11-22 | Cytarabine intrathecal | Y | N | 310025484 | AZACITIDINE |
| 310009876 | 310005359 | 1.61 | 56 | Palliative (P) | 2017-06-30 | 2017-07-04 | AXITINIB | 2 | N | 310025528 | CAPECITABINE + OXALIPLATIN |
| 310009877 | 310005360 | 0 | 9.8 | null | 2017-10-03 | 2017-10-12 | Alemtuzumab cond (RI ALLO CAMP100) | null | null | 310025547 | NIVOLUMAB |
| 310009878 | 310005361 | 1.62 | 179.7 | Palliative (P) | 2014-01-28 | 2014-07-31 | Vemurafenib | N | null | 310025578 | CETUXIMAB |
| 310009879 | 310005362 | 1.78 | 88 | Palliative (P) | 2016-07-31 | 2016-04-11 | INTERFERON | N | N | 310025608 | DABRAFENIB |
| 310009880 | 310005372 | 1.53 | 81.4 | Palliative (P) | 2013-11-22 | 2013-12-01 | Oxaliplatin + Modified de Gramont | null | null | 310025617 | FLUDARABINE + MELPHALAN |
| 310009881 | 310005374 | 1.78 | null | Curative (C) | 2017-03-05 | 2017-03-06 | CVP | N | null | 310025661 | DOXORUBICIN |
| 310009882 | 310005374 | 1.56 | 79 | Curative (C) | 2016-05-10 | 2016-05-10 | CAPECITABINE + CISPLATIN + EPIRUBICIN | null | N | 310025661 | TIP |
| 310009883 | 310005375 | 1.78 | 103.6 | Palliative (P) | 2015-10-20 | 2015-11-04 | DOXORUBICIN | 2 | N | 310025674 | ENZALUTAMIDE |
| 310009884 | 310008364 | 1.57 | 59.7 | Palliative (P) | 2015-08-29 | 2016-01-04 | Cisplatin + Paclitaxel | 2 | N | 310025687 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 310009885 | 310008366 | 1.45 | 55.8 | Disease modification (D) | 2017-08-06 | 2018-03-03 | ICON8B TRIAL | N | N | 310025703 | CEV |
| 310009886 | 310005381 | 1.54 | 50 | null | 2015-09-05 | 2015-09-30 | Hydroxycarbamide | N | N | 310025710 | HYDROXYCARBAMIDE |
| 310009887 | 310005387 | 1.75 | 64 | Curative (C) | 2014-03-03 | 2014-03-03 | Cisplatin + Etoposide po&iv 3 day | N | N | 310025718 | ARSENIC TRIOXIDE + TRETINOIN |
| 310009888 | 310005389 | 1.8 | 77.1 | Curative (C) | null | 2015-02-22 | ECF | N | N | 310025719 | THALIDOMIDE |
| 310009889 | 310005394 | 1.6 | 60 | Neo-adjuvant (N) | 2018-04-06 | 2018-04-12 | Carbo F | null | null | 310025731 | METHOTREXATE |
| 310009890 | 310005397 | 1.74 | 81.5 | Palliative (P) | 2016-03-19 | 2016-03-29 | RITUXIMAB + prednisolone + VINBLASTINE + prednisolone | 02 | N | 310025753 | ICE-R |
| 310009891 | 310010830 | 1.8 | null | Palliative (P) | 2016-08-26 | 2017-04-15 | PEG INTERFERON | null | null | 310000138 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB |
| 310009892 | 310005400 | 1.54 | 63.9 | Palliative (P) | 2015-09-11 | 2015-10-03 | FLUOROURACIL + IRINOTECAN | 2 | N | 310000155 | OLAPARIB |
| 310009893 | 310005401 | 1.74 | null | null | 2016-03-29 | 2016-04-19 | BLEOMYCIN | 02 | null | 310000191 | CTD |
| 310009894 | 310005402 | 1.62 | 71.6 | Adjuvant (A) | 2015-06-11 | 2015-06-13 | Capecitabine | N | N | 310000297 | EURO-EWING |
| 310009895 | 310005405 | null | 66.7 | Palliative (P) | 2018-05-20 | 2018-05-22 | Capecitabine (14 day) + Irinotecan | N | N | 310000433 | CISPLATIN + FLUOROURACIL |
| 310009896 | 310008381 | null | null | Palliative (P) | 2017-10-25 | 2017-11-22 | Cetuximab 7 day (Cycle 1) | N | null | 310000469 | TRASTUZUMAB |
| 310009897 | 310005413 | 1.55 | null | Curative (C) | 2017-02-19 | 2017-02-21 | GEFITINIB | 01 | null | 310000475 | BORTEZOMIB |
| 310009898 | 310005414 | 1.69 | null | Palliative (P) | 2018-03-05 | 2018-05-08 | CISPLATIN + ETOPOSIDE | N | N | 310000647 | OLAPARIB |
| 310009899 | 310005417 | 1.64 | 58.6 | Curative (C) | 2017-02-14 | 2017-02-15 | IPILIMUMAB + NIVOLUMAB | N | N | 310000661 | CETUXIMAB + RT |
| 310009900 | 310005419 | null | 78.3 | Palliative (P) | null | 2019-12-15 | Vemurafenib | 1 | null | 310000823 | TOPOTECAN |
| 310009901 | 310005421 | 0 | 75.6 | null | 2015-10-24 | 2016-02-09 | DOXORUBICIN | null | null | 310001071 | CETUXIMAB |
| 310009902 | 310005423 | 1.82 | 71 | null | 2017-06-08 | 2017-11-13 | DABRAFENIB + TRAMETINIB | 02 | N | 310001118 | RMS 2005 TRIAL |
| 310009903 | 310005428 | 1.52 | 61 | Palliative (P) | 2016-01-07 | 2016-01-07 | ICON8 TRIAL | Y | N | 310001253 | ICON TRIAL |
| 310009904 | 310005429 | 1.68 | 57 | Palliative (P) | 2017-07-06 | 2017-07-06 | IMATINIB | 02 | N | 310001330 | IVE + METHOTREXATE |
| 310009905 | 310005430 | 1.85 | 101.5 | Curative (C) | 2018-12-02 | 2018-12-02 | Cetuximab + Radiotherapy Maint | 02 | N | 310001357 | VINBLASTINE |
| 310009906 | 310005433 | 1.29 | 59.6 | Disease modification (D) | 2019-04-20 | 2019-04-21 | Cytarabine HD + Methotrexate HD | 2 | N | 310001395 | VINBLASTINE |
| 310009907 | 310008394 | 1.45 | 49.1 | Palliative (P) | 2016-02-06 | 2016-02-07 | Temozolomide 200mg/m2 | N | N | 310001625 | NIRAPARIB |
| 310009908 | 310010834 | 1.76 | 85 | Palliative (P) | null | 2019-03-21 | Lenalidomide Cycle 26 onwards (PAS) | 02 | N | 310001636 | CAPECITABINE + CISPLATIN |
| 310009909 | 310005437 | null | 71 | Palliative (P) | 2017-06-27 | 2017-08-10 | Vemurafenib | null | Y | 310001682 | TRABECTEDIN |
| 310009910 | 310005441 | null | 71.4 | Not known (9) | 2013-12-21 | 2013-12-21 | Cytarabine High Dose | 02 | N | 310001938 | BCG |
| 310009911 | 310005445 | 1.73 | 64 | null | 2017-10-27 | 2017-10-28 | BCG Intravesical | N | N | 310002273 | CETUXIMAB + RT |
| 310009912 | 310005446 | 1.84 | 92.8 | Not known (9) | 2015-04-18 | 2015-04-18 | TIP | N | N | 310002273 | CETUXIMAB |
| 310009913 | 310008401 | 1.6 | 59.7 | Curative (C) | 2017-04-27 | 2017-10-05 | ECX | null | N | 310002332 | TOPOTECAN |
| 310009914 | 310005449 | 1.54 | 46.8 | Palliative (P) | null | 2015-12-19 | CISPLATIN + FLUOROURACIL | 02 | null | 310002562 | OCTOPUS TRIAL |
| 310009915 | 310005452 | 1.59 | 66.8 | Curative (C) | 2010-08-23 | 2014-10-22 | BENDAMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | N | N | 310002632 | CHOEP |
| 310009916 | 310005454 | 1.61 | 72.9 | Curative (C) | 2015-08-06 | 2015-08-26 | ICON8 TRIAL | 1 | null | 310002632 | CYTARABINE INTRATHECAL |
| 310009917 | 310008405 | 1.52 | 151.6 | Palliative (P) | 2018-02-21 | 2018-02-21 | BCG Intravesical | N | N | 310003095 | PMITCEBO |
| 310009918 | 310005457 | null | 60 | null | 2017-04-03 | 2017-05-08 | Bevacizumab+Carbo+Gemcitabine | N | N | 310003110 | ERIBULIN |
| 310009919 | 310005458 | 1.5 | null | Disease modification (D) | null | 2017-12-31 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE | Y | null | 310003191 | CARBOPLATIN + PEMETREXED |